Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko
OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.
目的:相对于采用系统活检诊断为GG1癌的男性,采用靶向活检诊断为Gleason Grade Group (GG) 2癌的患者确定治疗的可能性和治疗后复发的风险。材料和方法我们使用一个大型三级中心登记处(HUS学术数据湖)进行了一项回顾性研究,以检索前列腺癌(PCa)的诊断、治疗和癌症复发的数据。我们纳入了1993年至2019年间通过系统活检检测到GG1型前列腺癌(n = 3317)或通过靶向活检检测到GG2型前列腺癌(n = 554)的患者。我们评估了治愈治疗和治疗后复发的风险。Kaplan-Meier曲线用于估计无治疗和无复发生存期,Cox比例风险回归用于评估治疗后复发风险。结果系统活检检测到GG1癌患者的中位治疗时间(31个月)明显长于靶向活检检测到GG2癌患者(4个月,P < 0.0001)。两组治愈后复发的风险相似,95%置信区间(CI)上界排除任何显著差异(风险比1.04,95% CI 0.75-1.43; P = 0.83)。结论与系统活检诊断为GG1的男性相比,基于mri靶向活检诊断为GG2的男性治疗后复发的风险相似,尽管他们更有可能接受根治性治疗。这些发现表明,在MRI时代GG2诊断的明显增加中,至少有一部分可能反映了重新分类,而不是更具侵袭性的疾病。需要改进风险分层,以确定哪些患有mri时代GG2癌的男性可能适合进行主动监测。
{"title":"Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.","authors":"Abderrahim-Oussama Batouche,Eugen Czeizler,Timo-Pekka Lehto,Andrew Erickson,Tolou Shadbahr,Teemu D Laajala,Joona Pohjonen,Tuomas Mirtti,Antti S Rannikko","doi":"10.1111/bju.70109","DOIUrl":"https://doi.org/10.1111/bju.70109","url":null,"abstract":"OBJECTIVETo determine the likelihood of definitive treatment and risk of post-treatment recurrence for patients with Gleason Grade Group (GG) 2 cancer diagnosed using targeted biopsies relative to men with GG1 cancer diagnosed using systematic biopsies.MATERIALS AND METHODSWe performed a retrospective study using a large tertiary centre registry (the HUS Acamedic data lake) to retrieve data on prostate cancer (PCa) diagnosis, treatment, and cancer recurrence. We included patients with either GG1 PCa detected by systematic biopsies (n = 3317) or GG2 PCa detected with targeted biopsies (n = 554) between 1993 and 2019. We assessed the risk of curative treatment and recurrence after treatment. Kaplan-Meier curves were used to estimate treatment- and recurrence-free survival, and Cox proportional hazards regression was used to evaluate the risk of post-treatment recurrence.RESULTSPatients with systematic biopsy-detected GG1 cancer had a significantly longer median time to treatment (31 months) than those with targeted biopsy-detected GG2 cancer (4 months; P < 0.0001). Risk of recurrence after curative treatment was similar in the two groups, with the upper bound of the 95% confidence interval (CI) excluding any significant difference (hazard ratio 1.04, 95% CI 0.75-1.43; P = 0.83).CONCLUSIONMen diagnosed with GG2 PCa based on MRI-targeted biopsy had a similar risk of recurrence after treatment compared to men with GG1 disease diagnosed using systematic biopsy, although they were more likely to undergo curative treatment. These findings suggest that at least a portion of the apparent increase in GG2 diagnoses in the MRI era may reflect reclassification rather than more aggressive disease. Improved risk stratification is needed to identify which men with MRI-era GG2 cancer may be suitable for active surveillance.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"14 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comment on 'Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract after spinal cord injury'.","authors":"Longtu Ma,Rui Lu,Zhilong Dong","doi":"10.1111/bju.70107","DOIUrl":"https://doi.org/10.1111/bju.70107","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"57 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich
{"title":"Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts.","authors":"Matthias May,Anton Kravchuk,Ralph M Wirtz,Thorsten H Ecke,Axel Heidenreich","doi":"10.1111/bju.70113","DOIUrl":"https://doi.org/10.1111/bju.70113","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"170 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145752614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Response to: ‘Expanding the evidence base for Uromonitor®: updated pooled performance across eight cohorts’","authors":"José Rubio‐Briones","doi":"10.1111/bju.70114","DOIUrl":"https://doi.org/10.1111/bju.70114","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"6 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145731055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler
{"title":"RE: Comment: ‘Male sex is a risk factor for detrusor pressure jeopardising the upper urinary tract in patients with spinal cord injury’","authors":"Collene E. Anderson, Veronika Birkhäuser, Martin W. G. Brinkhof, Thomas M. Kessler","doi":"10.1111/bju.70106","DOIUrl":"https://doi.org/10.1111/bju.70106","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"98 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145711403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
<p>Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.</p><p>